These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18163485)

  • 41. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
    Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
    Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.
    Moreland LW; Sewell KL; Trentham DE; Bucy RP; Sullivan WF; Schrohenloher RE; Shmerling RH; Parker KC; Swartz WG; Woodworth TG
    Arthritis Rheum; 1995 Sep; 38(9):1177-86. PubMed ID: 7575710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
    Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
    Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.
    Genovese MC; Bojin S; Biagini IM; Mociran E; Cristei D; Mirea G; Georgescu L; Sloan-Lancaster J
    Arthritis Rheum; 2013 Apr; 65(4):880-9. PubMed ID: 23359344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.
    Damjanov N; Tlustochowicz M; Aelion J; Greenwald M; Diehl A; Bhattacharya I; Peeva E; Menon S; Gourley I
    J Rheumatol; 2016 Dec; 43(12):2094-2100. PubMed ID: 27909139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial.
    Kavanaugh A; Genovese M; Baughman J; Kivitz A; Bulpitt K; Olsen N; Weisman M; Matteson E; Furst D; van Vollenhoven R; Anderson J; Cohen S; Wei N; Meijerink J; Jacobs C; Mocci S
    J Rheumatol; 2003 Mar; 30(3):449-54. PubMed ID: 12610799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
    Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
    Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.
    Landewé RB; Houbiers JG; Van den Bosch F; in't Hout J; Verschueren PC; Meijerink JH; van den Hoogen FH; Masek BA; Bruyn GA; Wouters JM; Voskuyl AE; van Laar JM; Bijlsma JJ; van der Heijde DM; Breedveld FC; van de Putte LB; Miltenburg AM; de Keyser F
    Ann Rheum Dis; 2010 Sep; 69(9):1655-9. PubMed ID: 19778914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.
    Rossi JF; Moreaux J; Hose D; Requirand G; Rose M; Rouillé V; Nestorov I; Mordenti G; Goldschmidt H; Ythier A; Klein B
    Br J Cancer; 2009 Oct; 101(7):1051-8. PubMed ID: 19789533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
    Stohl W; Merrill JT; McKay JD; Lisse JR; Zhong ZJ; Freimuth WW; Genovese MC
    J Rheumatol; 2013 May; 40(5):579-89. PubMed ID: 23547209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
    St Clair EW; Wagner CL; Fasanmade AA; Wang B; Schaible T; Kavanaugh A; Keystone EC
    Arthritis Rheum; 2002 Jun; 46(6):1451-9. PubMed ID: 12115174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G; Bresnihan B; Bear MB; McCabe D;
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.